NCCN Guidelines Reaffirm Support For Avastin In Metastatic Breast Cancer
The influential NCCN Clinical Practice Guidelines for Oncology should retain its recommendation supporting use of Genentech/Roche’s Avastin (bevacizumab) in metastatic breast cancer, the National Comprehensive Cancer Network expert breast cancer panel voted 24-0, with 1 abstention, at its July 10-12 meeting. NCCN recommendations are often used by payers in establishing formulary and coverage policies.
You may also be interested in...
Announcement follows similar moves by three smaller commercial payers earlier this year.